1 arrow rescue in relapsed medulloblastoma and germinoma.

2 re seen in patients with medulloblastoma and germinomas.

3  Seventy-one patients were enrolled (45 with germinoma and 26 with nongerminomatous GCT [NGGCT]).

4 of efficacy in the treatment of intracranial germinoma and it remains the standard therapy with which

5                      The CR rate was 84% for germinomas and 78% for NGGCT.

6 otherapy is the best treatment for localised germinomas and conclude that reduced-volume radiotherapy

7 tive therapy for patients with recurrent CNS germinomas and might be effective in patients with recur

8                    Four patients (three with germinomas and one with mixed GCT) presented with leptom

9 urgery in GCTs and the optimal treatment for germinomas as well as mixed malignant GCTs.

10                            Nine patients had germinomas; eight had mixed GCT.

11                                Patients with germinoma fared better than those with NGGCTs (P =.016 a

12 osarcoma (n = 1), neuroblastoma (n = 1), and germinoma (n = 1), for an overall response rate of 5%.

13 umor (n = 6), ependymoma (n = 3), and pineal germinoma (n = 1).

14               The remaining 184 patients had germinoma (n = 20), malignant teratoma (n = 55), embryon

15 ), astrocytoma (n = 10), ependymoma (n = 5), germinoma (n = 3), atypical teratoid rhabdoid tumor (n =

16 probability of surviving 2 years was .84 for germinoma patients and .62 for NGGCT.

17 optimum management of localised intracranial germinoma remains controversial.

18 n, testes, or ovaries, where they are termed germinomas, seminomas, or dysgerminomas, respectively.

19            Seven of nine (78%) patients with germinoma survived disease-free after HDC with a median

20 medulloblastoma (CR and three PRs), two with germinomas (two CRs), and one with ependymoma (one CR).